Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Biological therapies, such as denileukin diftitox, may interfere with the growth of cancer cells and slow the growth of chronic lymphocytic leukemia. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Key facts

Study ID

NCT00082940

Run by

Wake Forest University Health Sciences

Starts

2002-08-01

Expected to finish

2005-06-01

Last updated by the study team

2017-01-19

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Joseph Hospital Regional Cancer Center - Orange — Orange, California, United States
• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• Medical Center Vincennes — Vincennes, Indiana, United States
• Cancer Care Specialists — Houma, Louisiana, United States
• Feist-Weiller Cancer Center at Louisiana State University Health Sciences — Shreveport, Louisiana, United States
• Josephine Ford Cancer Center at Henry Ford Health System — Detroit, Michigan, United States
• Southeastern Medical Oncology Center — Goldsboro, North Carolina, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Gibbs Regional Cancer Center at Spartanburg Regional Medical Center — Spartanburg, South Carolina, United States
• Chattanooga Oncology and Hematology Associates — Chattanooga, Tennessee, United States
• Southwest Regional Cancer Center - Central — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.